Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03346135 | Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma | active not recruiting | Phase 2 | 31 | City of Hope Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT02213926 | An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma | active not recruiting | Phase 2 | 124 | Acerta Pharma BVINDUSTRY | 10 | Aug 4, 2026 | clinicaltrials |
| NCT03984448 |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas |
| active not recruiting |
| Phase 2 / Phase 3 |
| 363 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Aug 4, 2026 |
| clinicaltrials |
| NCT04320888 | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 3 | Aug 3, 2026 | clinicaltrials |
| NCT03888105 | A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies(ELM-2) | active not recruiting | Phase 2 | 515 | Regeneron PharmaceuticalsINDUSTRY | 14 | Jul 31, 2026 | clinicaltrials |
| NCT06425302 | A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma(GOLSEEK-2) | active not recruiting | Phase 2 | 95 | CelgeneINDUSTRY | 13 | Jul 31, 2026 | clinicaltrials |
| NCT02981628 | Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 80 | Children's Oncology GroupNETWORK | 2 | Jul 30, 2026 | clinicaltrials |
| NCT04439227 | Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) | active not recruiting | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03075696 | A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma | active not recruiting | Phase 1 / Phase 2 | 940 | Hoffmann-La RocheINDUSTRY | 13 | Jul 29, 2026 | clinicaltrials |
| NCT01574274 | SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma | active not recruiting | Phase 2 | 240 | Dana-Farber Cancer InstituteOTHER | 2 | Jul 28, 2026 | clinicaltrials |
| NCT02506933 | Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant | active not recruiting | Phase 2 | 102 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT04140162 | Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy | active not recruiting | Phase 2 | 57 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05141682 | Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia | active not recruiting | Phase 1 / Phase 2 | 11 | Jonathan BrammerOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | active not recruiting | Phase 2 | 1,377 | National Cancer Institute (NCI)NIH | 4 | Jul 24, 2026 | clinicaltrials |
| NCT05926765 | A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia(AQUAx2) | active not recruiting | Phase 2 | 290 | MeiraGTx, LLCINDUSTRY | 3 | Jul 24, 2026 | clinicaltrials |
| NCT05346809 | Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma | active not recruiting | Phase 2 | 8 | Divaya BhutaniOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT01059786 | Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia | active not recruiting | Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Jul 22, 2026 | clinicaltrials |
| NCT03739502 | A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant(HBO-UBC) | active not recruiting | Phase 2 | 64 | University of RochesterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04703192 | Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) | active not recruiting | Phase 2 | 155 | Daiichi SankyoINDUSTRY | 12 | Jul 20, 2026 | clinicaltrials |
| NCT05821088 | Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma | active not recruiting | Phase 2 | 37 | David Bond, MDOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06649695 | A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis | active not recruiting | Phase 2 | 30 | European Myeloma Network B.V.NETWORK | 6 | Jul 20, 2026 | clinicaltrials |
| NCT04439318 | Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) | active not recruiting | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04439357 | Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) | active not recruiting | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04783415 | Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | active not recruiting | Phase 2 | 12 | City of Hope Medical CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05690984 | Elimination of Minimal Residual Disease After Transplant(EMAT) | active not recruiting | Phase 2 | 30 | Medical College of WisconsinOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06385483 | Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) | active not recruiting | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06390826 | Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) | active not recruiting | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2026 | clinicaltrials |
| NCT01352520 | SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) | active not recruiting | Phase 2 | 79 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03282396 | Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma | active not recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03896737 | Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara | active not recruiting | Phase 2 | 401 | European Myeloma Network B.V.NETWORK | 3 | Jul 16, 2026 | clinicaltrials |
| NCT04564703 | Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients | active not recruiting | Phase 2 | 160 | Stichting European Myeloma NetworkNETWORK | 4 | Jul 16, 2026 | clinicaltrials |
| NCT02494700 | Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT06097832 | Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis(NEXICART-2) | active not recruiting | Phase 1 / Phase 2 | 45 | Nexcella Inc.INDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04822337 | Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06523621 | Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel | active not recruiting | Phase 2 | 1 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03213652 | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 4 | Jul 10, 2026 | clinicaltrials |
| NCT04419519 | Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax | active not recruiting | Phase 2 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05303792 | Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 68 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05451771 | Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis | active not recruiting | Phase 1 / Phase 2 | 53 | Columbia UniversityOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06300528 | Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas | active not recruiting | Phase 2 | 1 | University of UtahOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT01880567 | Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma | active not recruiting | Phase 2 | 113 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03269669 | Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma | active not recruiting | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04799275 | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | active not recruiting | Phase 2 / Phase 3 | 422 | National Cancer Institute (NCI)NIH | 1 | Jul 8, 2026 | clinicaltrials |
| NCT02690545 | Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL | active not recruiting | Phase 1 / Phase 2 | 38 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT03114865 | A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | active not recruiting | Phase 1 / Phase 2 | 44 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03331198 | Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | active not recruiting | Phase 1 / Phase 2 | 320 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT03533283 | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | active not recruiting | Phase 1 / Phase 2 | 211 | Hoffmann-La RocheINDUSTRY | 6 | Jul 6, 2026 | clinicaltrials |
| NCT04416451 | A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma | active not recruiting | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 5, 2026source: clinicaltrials